The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Open accessAbstract
The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Voriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 785
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Wingard, J. R., Carter, S. L., Walsh, T. J., Kurtzberg, J., Small, T. N., Baden, L. R., Gersten, I. D., Mendizabal, A. M., Leather, H. L., Confer, D. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268151 · Cited by 482
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
Brouwer, A. E., Rajanuwong, A., Chierakul, W., Griffin, G. E., Larsen, R. A., White, N. J., & Harrison, T. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16301-0 · Cited by 470
Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598327 · Cited by 457
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
The Clinical Pharmacokinetics of Itraconazole: An Overview
Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Van Cutsem, J., & Cauwenbergh, G. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02296.x · Cited by 404
Park, W. B., Kim, N.-H., Kim, K.-H., Lee, S. H., Nam, W.-S., Yoon, S. H., Song, K.-H., Choe, P. G., Kim, N. J., Jang, I.-J., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis599 · Cited by 399
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Treatment of invasive aspergillosis with itraconazole
Denning, D. W., Tucker, R. M., Hansen, L. H., & Stevens, D. A. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90475-0 · Cited by 364
Krishna, G., Moton, A., Ma, L., Medlock, M. M., & McLeod, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01034-08 · Cited by 349
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Self-citationTHE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN
Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., & Wood, N. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.731 · Cited by 330
Courtney, R., Wexler, D., Radwanski, E., Lim, J., & Laughlin, M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 327
Pharmacokinetics of itraconazole following oral administration to normal volunteers
Hardin, T. C., Graybill, J. R., Fetchick, R., Woestenborghs, R., Rinaldi, M. G., & Kuhn, J. G. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1310 · Cited by 299
Courtney, R., Pai, S., Laughlin, M., Lim, J., & Batra, V. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2788-2795.2003 · Cited by 299
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Dolton, M. J., Ray, J. E., Chen, S. C.-A., Ng, K., Pont, L. G., & McLachlan, A. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00626-12 · Cited by 290
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000315 · Cited by 276
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
Glasmacher, A., Prentice, A., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegovic, B., & Schmidt-Wolf, I. G. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.052 · Cited by 264
Tan, K., Brayshaw, N., Tomaszewski, K., Troke, P., & Wood, N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283837 · Cited by 256
Wheat, J., Hafner, R., Korzun, A. H., Limj, M. T., Spencer, P., Larsen, R. A., Hecht, F. M., & Powderly, W. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80311-8 · Cited by 245
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
Stamm, A. M., Diasio, R. B., Dismukes, W. E., Shadomy, S., Cloud, G. A., Bowles, C. A., Karam, G. H., & Espinel-Ingroff, A. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90691-7 · Cited by 244
Marks, D. I., Pagliuca, A., Kibbler, C. C., Glasmacher, A., Heussel, C., Kantecki, M., Miller, P. J. S., Ribaud, P., Schlamm, H. T., Solano, C., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08838.x · Cited by 243
Jang, S. H., Colangelo, P. M., & Gobburu, J. V. S. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.64 · Cited by 239
Denning, D. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.3.401 · Cited by 235
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231
Trifilio, S., Singhal, S., Williams, S., Frankfurt, O., Gordon, L., Evens, A., Winter, J., Tallman, M., Pi, J., & Mehta, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705754 · Cited by 229
Willems, L., van der Geest, R., & de Beule, K. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00338.x · Cited by 227
Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
Karlsson, M. O., Lutsar, I., & Milligan, P. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00751-08 · Cited by 227
Barone, J. A., Koh, J. G., Bierman, R. H., Colaizzi, J. L., Swanson, K. A., Gaffar, M. C., Moskovitz, B. L., Mechlinski, W., & Van de Velde, V (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.778 · Cited by 225
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-10 · Cited by 218
Self-citationSafety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
Raad, I. I., Graybill, J. R., Bustamante, A. B., Cornely, O. A., Gaona-Flores, V., Afif, C., Graham, D. R., Greenberg, R. N., Hadley, S., Langston, A., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/504328 · Cited by 217
Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis
Denning, D. W. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.10.2301 · Cited by 215
Voriconazole Pharmacokinetics and Pharmacodynamics in Children
Neely, M., Rushing, T., Kovacs, A., Jelliffe, R., & Hoffman, J. (2010) · Clinical Infectious Diseases · doi:10.1086/648679 · Cited by 214
Pascual, A., Csajka, C., Buclin, T., Bolay, S., Bille, J., Calandra, T., & Marchetti, O. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis437 · Cited by 207
Nussbaum, J. C., Jackson, A., Namarika, D., Phulusa, J., Kenala, J., Kanyemba, C., Jarvis, J. N., Jaffar, S., Hosseinipour, M. C., Kamwendo, D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649861 · Cited by 194
Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels
Boogaerts, M. A., Verhoef, G. E., Zachee, P., Demuynck, H., Verbist, L., & De Beule, K. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02299.x · Cited by 189
Dolton, M. J., Ray, J. E., Chen, S. C.-A., Ng, K., Pont, L., & McLachlan, A. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00802-12 · Cited by 188
Tucker, R. M., Denning, D. W., Hanson, L. H., Rinaldi, M. G., Graybill, J. R., Sharkey, P. K., Pappagianis, D., & Stevens, D. A. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.1.165 · Cited by 183
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S., Ortiz, R., Pennick, G., Verma, A., Pi, J., Stosor, V, Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177
Optimisation of Itraconazole Therapy Using Target Drug Concentrations
Poirier, M., & Cheymol, G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835060-00004 · Cited by 168
Thicot, G., Joosten, E., Boogaerts, M. A., Vande Pitte, J., & Cauwenbergh, G. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s94 · Cited by 162
Voriconazole concentrations and outcome of invasive fungal infections
Miyakis, S., van Hal, S. J., Ray, J., & Marriott, D. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02990.x · Cited by 159
High-dose itraconazole in the treatment of severe mycoses
Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J., & Graybill, J. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.707 · Cited by 155
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring
Imhof, A., Schaer, D. J., Schwarz, U., & Schanz, U. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11547 · Cited by 154
Therapeutic drug monitoring for triazoles
Hope, W. W., Billaud, E. M., Lestner, J. M., & Denning, D. W. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283184611 · Cited by 148
Self-citationBreakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
Glasmacher, A. G., Hahn, C., Leutner, C., Molitor, E., Wardelmann, E., Losem, C. J., Sauerbruch, T., Marklein, G., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00505.x · Cited by 147
Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients
Gubbins, P. O., Krishna, G., Sansone‐Parsons, A., Penzak, S. R., Li, D., Martinho, M., & Anaissie, E. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-06 · Cited by 146
Odds, F. C., Gerven, F. V., Espinel‐Ingroff, A., Bartlett, M. S., Ghannoum, M. A., Lancaster, M. V., Pfaller, M. A., Rex, J. H., Rinaldi, M. G., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.282 · Cited by 146
Krishna, G., Ma, L., Martinho, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00222-12 · Cited by 145
Krishna, G., Ma, L., Martinho, M., Preston, R. A., & O'Mara, E. M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks268 · Cited by 145
Lestner, J. M., & Hope, W. W. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.794785 · Cited by 143
Self-citationRepeated-Dose Pharmacokinetics of an Oral Solution of Itraconazole in Infants and Children
de Repentigny, L., Ratelle, J., Leclerc, J.-M., Cornu, G., Sokal, E. M., Jacqmin, P., & de Beule, K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.404 · Cited by 142
Hallucinations during Voriconazole Therapy
Zonios, D. I., Gea‐Banacloche, J., Childs, R., & Bennett, J. E. (2008) · Clinical Infectious Diseases · doi:10.1086/588844 · Cited by 139
Rodríguez-Tudela, J. L., Almirante, B., Rodríguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., & Cuenca-Estrella, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-07 · Cited by 137
Effect of omeprazole on the pharmacokinetics of itraconazole
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050438 · Cited by 135
Ueda, K., Nannya, Y., Kumano, K., Hangaishi, A., Takahashi, T., Imai, Y., & Kurokawa, M. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0296-3 · Cited by 131
Mitsani, D., Nguyen, M. H., Shields, R. K., Toyoda, Y., Kwak, E. J., Silveira, F. P., Pilewski, J. M., Crespo, M. M., Bermudez, C. A., Bhama, J. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05219-11 · Cited by 130
EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole
Arendrup, M. C., Cuenca‐Estrella, M., Lass‐Flörl, C., & Hope, W. W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03890.x · Cited by 129
Self-citationMatsumoto, K., Ikawa, K., Abematsu, K., Fukunaga, N., Nishida, K., Fukamizu, T., Shimodozono, Y., Morikawa, N., Takeda, Y., & Yamada, K. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.008 · Cited by 129
Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring
Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009) · Clinical Infectious Diseases · doi:10.1086/605499 · Cited by 129
Self-citationTherapeutic Drug Monitoring of Voriconazole
Brüggemann, R. J. M., Donnelly, J. P., Aarnoutse, R. E., Warris, A., Blijlevens, N. M. A., Mouton, J. W., Verweij, P. E., & Burger, D. M. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31817b1a95 · Cited by 126
Cartledge, J. D., Midgely, J., & Gazzard, B. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.477 · Cited by 124
de Velde, V. J. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · PubMed · Cited by 116
Population Pharmacokinetics of Voriconazole in Adults
Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00702-11 · Cited by 116
Self-citationMavridou, E., Brüggemann, R. J. M., Melchers, W. J. G., Mouton, J. W., & Verweij, P. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00931-09 · Cited by 112
Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults
Lebeaux, D., Lanternier, F., Elie, C., Suárez, F., Buzyn, A., Viard, J., Bougnoux, M., Lecuit, M., Jullien, V., & Lortholary, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-09 · Cited by 104
Hamada, Y., Seto, Y., Yago, K., & Kuroyama, M. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0363-6 · Cited by 102
In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata
Normark, S. J., & Schönebeck, J. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.3.114 · Cited by 100
de Velde, V. J. S. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02973.x · Cited by 99
Clinical Pharmacokinetics of Systemically Administered Antimycotics
Bellmann, R. (2007) · Current Clinical Pharmacology · doi:10.2174/157488407779422311 · Cited by 98
Andes, D. R., & van Ogtrop, M. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 96
A rapid HPLC assay for voriconazole in human plasma
Gage, R., & Stopher, D. A. (1998) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(98)00004-1 · Cited by 94
Treatment of invasive aspergillosis
Denning, D. W. (1994) · Journal of Infection · doi:10.1016/s0163-4453(94)95941-2 · Cited by 91
Chhun, S., Rey, E., Tran, A., Lortholary, O., Pons, G., & Jullien, V. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.01.021 · Cited by 91
Soler‐Palacín, P., Frick, M. A., Martín‐Nalda, A., Lanaspa, M., Pou, L., Rosello, E., de Heredia, C. D., & Figueras, C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr517 · Cited by 90
Farowski, F., Cornely, O. A., Vehreschild, J. J., Hartmann, P., Bauer, T., Steinbach, A., Rüping, M. J. G. T., & Müller, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01276-09 · Cited by 81
Vandewoude, K., Vogelaers, D., Decruyenaere, J., Jaqmin, P., De Beule, K., Van Peer, A., Woestenborghs, R., Groen, K., & Colardyn, F. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.12.2714 · Cited by 79
Ducharme, M. P., Slaughter, R. L., Warbasse, L. H., Chandrasekar, P. H., de Velde, V. V., Mannens, G., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90017-9 · Cited by 78
Driscoll, T. A., Frangoul, H., Nemecek, E. R., Murphey, D., Yu, L. C., Blumer, J. L., Krance, R. A., Baruch, A. M., & Liu, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05010-11 · Cited by 78
Safety of Voriconazole and Dose Individualization
Lutsar, I., Hodges, M. R., Tomaszewski, K. E., Troke, P. F., & Wood, N. (2003) · Clinical Infectious Diseases · doi:10.1086/374248 · Cited by 77
Campoli, P., Abdallah, Q. A., Robitaille, R., Solis, N. V., Fielhaber, J. A., Kristof, A. S., Laverdière, M., Filler, S. G., & Sheppard, D. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00637-11 · Cited by 77
The pharmacokinetics of oral itraconazole in AIDS patients
Smith, D., de Velde, V. V., Woestenborghs, R. J. H., & Gazzard, B. (1992) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1992.tb05478.x · Cited by 77
Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050437 · Cited by 72
Flucytosine therapeutic monitoring: 15 years experience from the UK
Pasqualotto, A. C., Howard, S. J., Moore, C. B., & Denning, D. W. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl550 · Cited by 72
Hoenigl, M., Raggam, R. B., Salzer, H. J. F., Valentin, T., Valentin, A., Zollner‐Schwetz, I., Strohmeier, A. T., Seeber, K., Wölfler, A., Sill, H., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.02.002 · Cited by 70
Driscoll, T. A., Yu, L. C., Frangoul, H., Krance, R. A., Nemecek, E. R., Blumer, J. L., Arrieta, A. C., Graham, M. L., Bradfield, S. M., Baruch, A. M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00531-11 · Cited by 70
Hennig, S., Wainwright, C. E., Bell, S. C., Miller, H., Friberg, L. E., & Charles, B. G. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645110-00004 · Cited by 65
Shields, R. K., Clancy, C. J., Vadnerkar, A., Kwak, E. J., Silveira, F. P., Abdel-Massih, R. C., Pilewski, J. M., Crespo, M. M., Toyoda, Y., Bhama, J. K., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01325-10 · Cited by 64
Voriconazole in the management of nosocomial invasive fungal infections
Pemán, J., Salavert, M., Cant�n, E., Jarque, I., Rom, E., Zaragoza, R., Viudes, �., & Gobernado, M. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.2.129 · Cited by 63
Bryant, A. M., Slain, D., Cumpston, A., & Craig, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.021 · Cited by 61
Ráčil, Z., Winterová, J., Kouba, M., Žák, P., Malášková, L., Burešová, L., Tošková, M., Lengerová, M., Kocmanová, I., Weinbergerová, B., et al. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02186.x · Cited by 58
Krishna, G., Ma, L., Vickery, D., Yu, X. Y., Wu, I., Power, E., Beresford, E., & Komjathy, S. F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00889-09 · Cited by 55
Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards
Law, D., Moore, C. B., & Denning, D. W. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1561 · Cited by 55
Abdel‐Rahman, S. M., Jacobs, R. F., Massarella, J. W., Kauffman, R. E., Bradley, J. S., Kimko, H. C., Kearns, G. L., Shalayda, K., Curtin, C. R., Maldonado, S., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00297-07 · Cited by 54
Eiden, C., Meniane, J.-C., Peyrière, H., Eymard‐Duvernay, S., Falher, G. L., Céballos, P., Fegueux, N., Cociglio, M., Reynes, J., & Hillaire‐Buys, D. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1288-9 · Cited by 51
Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis
Schmitt, C., Pérel, Y., Harousseau, J., Lemerle, S., Chwetzoff, E., Moing, J. P. L., & Levron, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1561-1564.2001 · Cited by 51
Brüggemann, R. J. M., Touw, D. J., Aarnoutse, R. E., Verweij, P. E., & Burger, D. M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00901-08 · Cited by 51
Hope, W. W., Warn, P. A., Sharp, J., Howard, S. J., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., & Denning, D. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00369-06 · Cited by 49
Self-citationSoltani, M., Tobin, C. M., Bowker, K. E., Sunderland, J., MacGowan, A. P., & Lovering, A. M. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.07.013 · Cited by 46
Simon, A., Besuden, M., Vezmar, S., Hasan, C., Lampe, D., Kreutzberg, S., Glasmacher, A. G., Bode, U., & Fleischhack, G. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0125-7 · Cited by 45
Dosing guidelines for fluconazole in patients with renal failure
Cousin, L. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg363 · Cited by 44
van de Sande, W. W. J., Mathôt, R. A. A., ten Kate, M. T., van Vianen, W., Tavakol, M., Rijnders, B. J. A., & Bakker‐Woudenberg, I. A. J. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-08 · Cited by 43
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases
Müller, C., Arndt, M., Queckenberg, C., Cornely, O. A., & Theisohn, M. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01297.x · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
High-Dose Fluconazole Therapy in Patients with Severe Fungal Infections
Voss, A., & Pauw, B. E. D. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050252 · Cited by 38
Validation of rapid and simple LC–MS/MS method for determination of voriconazole in rat plasma
de Araújo, B. V., Conrado, D. J., Palma, E. C., & Costa, T. D. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.03.026 · Cited by 36
Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Warn, P. A., & Hope, W. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01111-12 · Cited by 36
Self-citationPosaconazole: The Case for Therapeutic Drug Monitoring
Howard, S. J., Felton, T., Gómez‐López, A., & Hope, W. W. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31823cdeac · Cited by 32
Self-citationCross, L. J. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.95 · Cited by 31
Rochat, B., Pascual, A., Pesse, B., Lamoth, F., Sanglard, D., Decosterd, L. A., Billé, J., & Marchetti, O. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00022-10 · Cited by 30
Efficacy of Voriconazole in a Guinea Pig Model of Invasive Trichosporonosis
Serena, C., Gilgado, F., Mariné, M., Pastor, F. J., & Guarro, J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00045-06 · Cited by 30
Antifungal Therapeutic Drug Monitoring
Lewis, R. E. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0023-9 · Cited by 29
Laboratory monitoring of antifungal chemotherapy
Shivji, A., Noble, M., & Bernstein, M. (1991) · The Lancet · doi:10.1016/0140-6736(91)91489-h · Cited by 28
Gómez‐López, A., Cendejas‐Bueno, E., Cuesta, I., García‐Rodríguez, J., Rodríguez-Tudela, J. L., Gutiérrez-Altés, A., & Cuenca‐Estrella, M. (2012) · Medical Mycology · doi:10.3109/13693786.2011.630039 · Cited by 27
Tremor: a newly described adverse event with long-term itraconazole therapy
Lestner, J. M., & Denning, D. W. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.174706 · Cited by 23
Okuda, T., Okuda, A., Watanabe, N., TAKAO, M., & 高柳, 和. (2008) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.128.1811 · Cited by 20
Al-Nakeeb, Z., Sudan, A., Jeans, A. R., Gregson, L., Goodwin, J., Warn, P. A., Felton, T., Howard, S. J., & Hope, W. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00141-12 · Cited by 15
Self-citationPosaconazole Serum Level on Day 2 Predicts Steady State Posaconazole Serum Level
Green, M. R., & Woolery, J. E. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31823cef77 · Cited by 15
Odabaşı, Z., Paetznick, V. L., Rodriguez, J. R., Chen, E., Rex, J. H., Leitz, G. J., & Ostrosky-Zeichner, L. L. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01733.x · Cited by 6
Uchida, K., Shimogawara, K., & Yamaguchi, H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq475 · Cited by 6
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
How to bolster the antifungal pipeline
Denning, D. W., & Bromley, M. J. (2015) · Science · doi:10.1126/science.aaa6097 · Cited by 481
Husain, S., & Camargo, J. F. (2019) · Clinical Transplantation · doi:10.1111/ctr.13544 · Cited by 302
Agarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Soundappan, K., Garg, M., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 261
Metadata
- Authors
- Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-29
- Volume
- 69
- Issue
- 5
- Pages
- 1162-1176
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2101785863
- Cited by
- 716
- References
- 133
- FWCI
- 23.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.